Charles River Laboratories International Inc (CRL, Financial) has recently captured the attention of investors and financial analysts, thanks to its strong financial performance. With a current share price of $218.67, Charles River Laboratories International Inc has enjoyed a daily increase of 1.52%, and a notable three-month growth of 6.67%. A detailed analysis, supported by the GF Score, indicates that Charles River Laboratories International Inc is poised for significant future growth.
What Is the GF Score?
The GF Score is a proprietary stock performance ranking system developed by GuruFocus. It evaluates stocks based on five key aspects of valuation, which have shown a strong correlation with long-term stock performance from 2006 to 2021. Stocks with higher GF Scores typically yield higher returns. The GF Score ranges from 0 to 100, with 100 indicating the highest potential for outperformance. Charles River Laboratories International Inc boasts a GF Score of 92, signaling strong future performance potential.
- Financial strength rank: 5/10
- Profitability rank: 10/10
- Growth rank: 9/10
- GF Value rank: 7/10
- Momentum rank: 5/10
Understanding Charles River Laboratories International Inc Business
Founded in 1947, Charles River Laboratories International Inc is a frontrunner in drug discovery and development services. The company's market cap stands impressively at $11.18 billion, with sales reaching $4.06 billion. It operates through several segments, including the provision of animal models for laboratory testing, discovery services for drug development, and manufacturing support through microbial solutions and biologics testing services. This diverse service offering underscores its pivotal role in preclinical and early-stage pharmaceutical development.
Profitability and Growth Metrics
Charles River Laboratories International Inc's Operating Margin has shown a positive trend over the past five years, increasing from 13.40% in 2019 to 14.95% in 2023. This growth in profitability is complemented by a strong Predictability Rank of 5.0 stars, highlighting consistent operational performance and reliability for investors.
The company's commitment to expansion is evident in its Growth rank of 9/10. With a 3-Year Revenue Growth Rate of 11.6%, Charles River Laboratories International Inc outperforms 64.82% of its peers in the Medical Diagnostics & Research industry. Additionally, its EBITDA has grown impressively over the past five years, further solidifying its growth trajectory.
Conclusion
Considering Charles River Laboratories International Inc's robust financial strength, exceptional profitability, and consistent growth metrics, the GF Score highlights the company's strong position for potential market outperformance. Investors looking for similar opportunities can explore other companies with high GF Scores through the GF Score Screen.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
